This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Winners & Losers: Alexza, Geron

(Biotech winners and losers item updated for closing stock prices.)

NEW YORK ( TheStreet) -- Alexza Pharmaceuticals (ALXA - Get Report) had the most unfortunate story in the biotech library Monday, as investors stripped more than half the market cap from the company's stock after the Food and Drug Administration denied approval of Alexza's treatment for schizophrenia and bipolar disorder.

Called AZ-004 and co-marketed with Valeant Pharmaceuticals (VRX), the treatment takes a generic drug called loxapine and delivers it to patients through an inhaler.

The FDA, however, said it had safety concerns about how the inhaled doses affected the lungs. Some patients in Phase 1 trials exhibited decreased pulmonary function, the FDA said.

In frantic trading Monday, Alexza shares ended the session at $1.38, down $1.65, or 54.4%. Volume exceeded 16 million shares, more than 20 times the daily average turnover in the name.

Elsewhere in the biotech sector, stocks were trading mixed. The Nasdaq Biotechnology Index declined 2.35 points to 908.39.

Among notable gainers, Geron (GERN - Get Report) shares rose 6.4% to $5.67 on heavy volume after the company announced it had launched a Phase 1 human clinical trial of a stem-cell-based treatment for spinal cord injuries.

The study is seminal -- and not just for the controversial Geron. The study marks the first time that stem cells removed from a human embryo will be tested in a human being. Geron's hope is that the cells will fix spinal nerve damage soon after injuries occur, thereby avoiding permanent paralysis.

The Geron trial comes after political skirmishing at the highest levels. Former President George W. Bush had famously placed restrictions on the use of federal funds for stem-cell research -- restrictions lifted by President Obama and upheld by a U.S. appeals court in September. Development of the Geron drug has partly been funded by a handful of states that rebelled against Bush's restrictions and offered grants on their own.

Among other winners in the land of experimental medicines, Pozen (POZN - Get Report) saw its shares rise steeply Monday after the European Union approved the company's pain reliever Vimovo for sale on the Continent. AstraZenca (AZN) is Pozen's partner in the development of the drug, which combines naproxen with the British pharma giant's heartburn blockbuster Nexium.

Pozen shares closed the session at $7.29, up 7.5%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
WCRX $0.00 0.00%
OPTR $0.00 0.00%
ALXA $2.07 2.50%
GERN $3.78 -2.50%
POZN $7.76 0.91%

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs